切换至 "中华医学电子期刊资源库"

中华腔镜泌尿外科杂志(电子版) ›› 2017, Vol. 11 ›› Issue (06) : 404 -406. doi: 10.3877/cma.j.issn.1674-3253.2017.06.011

所属专题: 文献

临床研究

MR扩散加权成像对膀胱尿路上皮癌的诊断价值
孟占鳌1, 何娅娣2, 夏桃林3, 罗子寰4, 陈晓波4, 高新4, 李辽源4,()   
  1. 1. 510630 广州,中山大学附属第三医院放射科
    2. 510630 广州,中山大学附属第三医院体检中心
    3. 528000 佛山市第一人民医院泌尿外科
    4. 510630 广州,中山大学附属第三医院泌尿外科
  • 收稿日期:2017-08-15 出版日期:2017-12-01
  • 通信作者: 李辽源
  • 基金资助:
    国家自然科学基金项目(81502206); 广东省自然科学基金项目(2014A030313088)

The role of diffusion-weighted MR imaging in the diagnosis of bladder urothelial cancer

Zhanao Meng1, Yadi He2, Taolin Xia3, Zihuan Luo4, Xiaobo Chen4, Xin Gao4, Liaoyuan Li4,()   

  1. 1. Department of Radiology, the Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510630, China
    2. Department of Physical Examination, the Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510630, China
    3. Department of Urology, the First People's Hospital of Foshan City, Guangdong 528000, China
    4. Department of Urology, the Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510630, China
  • Received:2017-08-15 Published:2017-12-01
  • Corresponding author: Liaoyuan Li
  • About author:
    Corresponding author: Li Liaoyuan, Email:
引用本文:

孟占鳌, 何娅娣, 夏桃林, 罗子寰, 陈晓波, 高新, 李辽源. MR扩散加权成像对膀胱尿路上皮癌的诊断价值[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2017, 11(06): 404-406.

Zhanao Meng, Yadi He, Taolin Xia, Zihuan Luo, Xiaobo Chen, Xin Gao, Liaoyuan Li. The role of diffusion-weighted MR imaging in the diagnosis of bladder urothelial cancer[J/OL]. Chinese Journal of Endourology(Electronic Edition), 2017, 11(06): 404-406.

目的

探索MR扩散加权成像(DWI)对膀胱尿路上皮癌的诊断价值。

方法

从2015年6月至2016年12月,将我院已进行MR扩散加权成像检查共72例膀胱疾病患者,根据病理结果分为膀胱良性疾病组(n=23)和膀胱尿路上皮癌组(n=49),比较膀胱良性疾病组和膀胱尿路上皮癌组术前的肿瘤平均表观扩散系数(ADC)值,采用受试运算特性(ROC)方法确定最佳诊断Cut-off值。

结果

膀胱良性疾病组和膀胱尿路上皮癌术前ADC值分别为(1.86±0.40)×10-3 mm2/s和(0.93±0.11)×10-3 mm2/s,差别具有统计学意义(P<0.01);ADC值在肿瘤分级间的差别有统计学意义;ADC值诊断膀胱尿路上皮癌的ROC曲线下面积为0.705;ADC值诊断膀胱尿路上皮癌时兼顾敏感性和特异性的最佳Cut-off值为1.32×10-3 mm2/s,此Cut-off值的敏感性和特异性分别为87.2%和82.9%。

结论

MR扩散加权成像ADC值可作为一种早期诊断膀胱尿路上皮癌的客观指标。

Objective

To evaluate the value of diffusion-weighted MR imaging in diagnosis of urothelial cancer.

Methods

From June 2015 to December 2016, 72 consecutive patients with suspicious bladder lesions were accessed in our hospital. According to the results of pathological examination, the patients were divided into two groups: benign lesions group (n=23) and urothelial cancer group (n=49). The apparent diffusion coefficient (ADC) values of all patients was analyzed. The receiver operating characteristic (ROC) curves were generated by plotting the sensitivity versus specificity. Area under the cures was calculated for ADC assay.

Results

There was significant difference in ADC values between benign lesions group and urothelial cancer group [(1.86±0.40)×10-3mm2/s vs (0.93±0.11) ×10-3mm2/s, P<0.01]. Area under the ROC curves of ADC values were 0.705. The specificity and sensitivity of ADC values were 82.9% and 87.2% respectively at the optimum cutoff value (1.32×10-3 ) mm2/s.

Conclusions

ADC value could provide an objective and reliable biomarker for the early diagnosis of bladder urothelial cancer.

表1 两组患者的一般情况比较(±s
表2 ADC值诊断膀胱尿路上皮癌的效能分析
[1]
He YD, Luo ZH, Yang M, et al. Prospective validation of DACH2 as a novel biomarker for prediction of metastasis and prognosis in muscle-invasive urothelial carcinoma of the bladder[J]. Biochem Biophys Res Commun, 2015, 459(3): 416-423.
[2]
Pickles MD, Gibbs P, Lowry M, et al, Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer[J]. Magn Reson Imaging, 2006, 24(7): 843-847.
[3]
Moffat BA, Chenevert TL, Lawrence TS, et al, Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinica brain tumor response[J]. Proc Natl Acad Sci USA, 102(15): 5524-5529.
[4]
Palou J, Algaba F, Vera I, et al. Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guérin[J]. Eur Urol, 2009, 56(5): 829-836.
[5]
van den Bosch S, Alfred Witjes J. Long-term Cancer-specific Survival in Patients with High-risk, Non-muscle-invasive Bladder Cancer and Tumour Progression: a systematic review[J]. Eur Urol, 2011, 60(3): 493-500.
[6]
Cancer GN. Comprehensive molecular characterization of urothelial bladder carcinoma[J]. Nature, 2014, 507(7492): 315-322.
[7]
李辽源,吴杰英,刘绍远,等. 膀胱尿路上皮癌组织中DACH2的表达及临床意义[J/CD]. 中华腔镜泌尿外科杂志:电子版, 2016, 10(6): 45-48.
[8]
Li LY, Yang M, Zhang HB, et al. Urinary fibronectin as a predictor of a residual tumour load after transurethral resection of bladder transitional cell carcinoma[J]. BJU Int, 2008, 102(5): 566-571.
[9]
Matsuki M, Inada Y, Tatsugami F, et al. Diffusion-weighted Mr imaging for urinary bladder carcinoma: initial results[J]. Eur Radiol, 2007, 17(1): 201-204.
[10]
Qayyum A. Diffusion-weighted imaging in the abdomen and pelvis: concepts and applications[J]. Radiographics, 2009, 29(6): 1797-1810.
[11]
Panebianco V, Barchetti F, De Haas RJ, et al. Improving staging in bladder cancer: the increasing role of multiparametric magnetic resonance imaging[J]. Eur Urol Focus, 2016, 2(2): 113-121.
[12]
Bagheri MH, Ahlman MA, Lindenberg L, et al. Advances in medical imaging for the diagnosis and management of common genitourinary cancers[J]. Urol Oncol, 2017, 35(7): 473-491.
[13]
Lim KS, Tan CH. Diffusion-weighted MRI of adult male pelvic cancers[J]. Clin Radiol, 2012, 67(9): 899-908.
[14]
Nakamura Y, Yoshida S, Tanaka H, et al. Potential utility of Diffusion-Weighted magnetic resonance imaging in diagnosis of residual bladder cancer before second transurethral resection[J]. Urol Int, 2017, 98(3): 298-303.
[15]
Lee M, Shin SJ, Oh YT, et al. Non-contrast magnetic resonance imaging for bladder cancer: fused high b value diffusion-weighted imaging and T2-weighted imaging helps evaluate depth of invasion[J]. Eur Radiol, 2017, 27(9): 3752-3758.
[1] 王亚红, 蔡胜, 葛志通, 杨筱, 李建初. 颅骨骨膜窦的超声表现一例[J/OL]. 中华医学超声杂志(电子版), 2024, 21(11): 1089-1091.
[2] 唐金侨, 叶宇佳, 王港, 赵彬, 马艳宁. 医学影像学检查方法在颞下颌关节紊乱病中临床应用研究进展[J/OL]. 中华口腔医学研究杂志(电子版), 2024, 18(06): 406-411.
[3] 中国医师协会肝癌专业委员会. 肝细胞癌伴微血管侵犯诊断和治疗中国专家共识(2024版)[J/OL]. 中华普通外科学文献(电子版), 2024, 18(05): 313-324.
[4] 赵林娟, 吕婕, 王文胜, 马德茂, 侯涛. 超声引导下染色剂标记切缘的梭柱型和圆柱型保乳区段切除术的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 634-637.
[5] 屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[6] 熊鹰, 林敬莱, 白奇, 郭剑明, 王烁. 肾癌自动化病理诊断:AI离临床还有多远?[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 535-540.
[7] 中华医学会器官移植学分会. 肝移植术后缺血性胆道病变诊断与治疗中国实践指南[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 739-748.
[8] 郑大雯, 王健东. 胆囊癌辅助诊断研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 769-773.
[9] 王秋生. 胆道良性疾病诊疗策略[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 779-782.
[10] 袁雨涵, 杨盛力. 体液和组织蛋白质组学分析在肝癌早期分子诊断中的研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 883-888.
[11] 李浩, 陈棋帅, 费发珠, 张宁伟, 李元东, 王硕晨, 任宾. 慢性肝病肝纤维化无创诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 863-867.
[12] 谭瑞义. 小细胞骨肉瘤诊断及治疗研究现状与进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 781-784.
[13] 王子阳, 王宏宾, 刘晓旌. 血清标志物对甲胎蛋白阴性肝细胞癌诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 677-681.
[14] 陈慧, 邹祖鹏, 周田田, 张艺丹, 张海萍. 皮肤镜对头皮红斑性皮肤病辅助鉴别诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 692-698.
[15] 胡云鹤, 周玉焯, 付瑞瑛, 于凡, 李爱东. CHS-DRG付费制度下GB1分组住院费用影响因素分析与管理策略探讨[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 568-574.
阅读次数
全文


摘要